Wavefront-optimized surface ablation with the Allegretto Wave Eye-Q excimer laser platform: 12-month visual and...

To evaluate the wavefront-optimized algorithm of the Allegretto Wave Eye-Q (Wavelight AG) 400-Hz excimer laser platform.

Three hundred three eyes of 303 patients treated with advanced surface ablation were evaluated prospectively. Topical mitomycin C (MMC) was used when ablation was ≥80 μm. Efficacy, safety, and predictability at 12 months were quantified with subjective refraction, visual acuity (logMAR), and slit-lamp examination.

Mean postoperative uncorrected distance visual acuity (UDVA) was 20/20.5 (0.01±0.05 logMAR). Postoperative UDVA was equal or better than preoperative corrected distance visual acuity (CDVA) in 94.7% of eyes. Efficacy index was 1.05. Corrected distance visual acuity was maintained (93.7%) or improved (5.9%) in 99.6% of treated eyes. No patient lost ≥2 lines. Safety index was 1.05. Haze at 12 months was grade ≤0.5 in 98% of treated eyes and grade ≤1 in 100% of treated eyes. Mean postoperative manifest refraction spherical equivalent (MRSE) was -0.03±0.15 diopters (D). Postoperative MRSE was within ±0.50 D in 99% of eyes. Overcorrection was documented in 0.66% and undercorrection in 0.33% of eyes.

The wavefront-optimized algorithm of the Allegretto Wave Eye-Q excimer laser platform showed good efficacy, safety, and predictability in advanced surface ablation, with or without MMC intraoperative use.